The Commonwealth Cancer Consortium, Inc. – Trademark Portfolio
Entity Type: 03
The Commonwealth Cancer Consortium, Inc. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 2 filings in this category. The portfolio also extends into Class 36 (Insurance & Financial) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include BREAK THROUGH CANCER. The owner is based in Sherborn, MA.
Sherborn, MA 01770
Showing of trademarks Trademarks
Trademark Classifications
The Commonwealth Cancer Consortium, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does The Commonwealth Cancer Consortium, Inc. have?
The Commonwealth Cancer Consortium, Inc. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does The Commonwealth Cancer Consortium, Inc. file in?
The Commonwealth Cancer Consortium, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 36 (Insurance & Financial). Class 35 covers advertising; business management; business administration; office functions.
What are The Commonwealth Cancer Consortium, Inc.'s most well-known trademarks?
The Commonwealth Cancer Consortium, Inc.'s registered trademark portfolio includes well-known marks such as BREAK THROUGH CANCER. These are among 2 currently registered trademarks in the portfolio.
What is The Commonwealth Cancer Consortium, Inc.'s trademark registration success rate?
The Commonwealth Cancer Consortium, Inc. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.